Innovations in onco-hematology in 2018

Violaine Havelange (1), Xavier Poire (1), Jean-Philippe Defour (2), Stefan N Constantinescu (3), Pascale Saussoy (2), Eric Van Den Neste (1), Sarah Bailly (1) Published in the journal : February 2019 Category : Onco-Hématologie

Summary :

In 2018, major developments have been achieved in the diagnostic and therapeutic fields of CAR-T cell immunotherapy, next-generation sequencing (NGS), and targeted therapies. Several studies have demonstrated the benefits of CAR-T cells in refractory or relapsing diffuse large B-cell lymphomas. NGS is a major breakthrough in the diagnosis and management of patients with myeloid neoplasia and represents an important prognostic tool that will probably replace many other conventional factors in the future. Finally, several targeted therapies reviewed in this article are about to revolutionize the management of acute myeloblastic leukemia.

Key words

Relapsing diffuse B-cell lymphoma, immunotherapy, CAR-T cells, next-generation sequencing, targeted therapies, acute myeloblastic leukemia